StreetInsider.com News Articles

Form 6-K BIOHARVEST SCIENCES INC. For: Oct 13

Tue, 13 Oct 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20261013/27181747.html

BioHarvest's olive cell compound reaches commercial readiness for licensing

Tue, 13 Oct 2026 07:05:32 -0400

BioHarvest Sciences Inc. (NASDAQ: BHST) announced that its proprietary Olive Cell composition has reached commercial readiness and is available for licensing through its contract development and manufacturing organization (CDMO) business.

The milestone covers completion of plant-cell development, large-scale bioreactor scale-up, commercial manufacturing validation at the company's GMP facility, and a self-affirmed U.S. Generally Recognized as Safe (GRAS) process for applicable intended uses. The self-affirmed GRAS conclusion does not constitute FDA approval.

Derived from Olea europaea fruit, the Olive Cell composition is a standardized olive fruit cell powder whose primary polyphenol is Verbascoside, a hydroxytyrosol derivative. The company states the composition delivers Verbascoside

BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

Tue, 13 Oct 2026 07:00:00 -0400

Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility

Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization

High-potency proprietary olive-derived Verbascoside composition demonstrates promising dose-dependent preclinical activity across liver steatosis and fibrosis models, with potential for development across multiple health and wellness categories

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™

BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

Tue, 13 Oct 2026 07:00:00 -0400

Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization

Form 6-K BIOHARVEST SCIENCES INC. For: Oct 08

Thu, 08 Oct 2026 14:32:00 -0400

si-local-file:///var/storage/secattach/20261008/27166575.html

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Thu, 08 Oct 2026 08:00:00 -0400

Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme.

The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.

This achievement marks continued positive progress in the collaboration, with both companies encouraged by the results achieved to date.

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Thu, 08 Oct 2026 08:00:00 -0400

Progress demonstrates that BioHarvest's Botanical Synthesis(TM) platform is capable of producing the targeted next-generation sweetening solution

The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution.

This achievement marks continued positive progress in the collaboration, with both companies encouraged by the results achieved to date.

Form 6-K BIOHARVEST SCIENCES INC. For: Oct 01

Fri, 02 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261002/27138367.html

BioHarvest Sciences launches share repurchase program of up to 5%

Tue, 29 Sep 2026 07:02:45 -0400

BioHarvest Sciences Inc. (NASDAQ: BHST) announced that its Board of Directors has authorized a share repurchase program structured as a normal course issuer bid (NCIB), allowing the company to buy back up to 5% of its outstanding common shares.

The maximum number of shares eligible for repurchase is 1,133,392. The program will not begin earlier than five days following the announcement and will terminate after 12 months, once the maximum number of shares has been repurchased, or upon earlier termination at the company's discretion.

All purchases will be executed on the Nasdaq Stock Market in compliance with Rule 10b-18 under the U.S.

BioHarvest Sciences Announces Share Repurchase Program

Tue, 29 Sep 2026 07:00:00 -0400

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in accordance with Canadian practices as a normal course issuer bid (the "NCIB").

The Company's Board of Directors believes that the market price of the Common Shares may not fully reflect the underlying value of the Company's business and future growth prospects. Consequently,

BioHarvest Sciences Announces Share Repurchase Program

Tue, 29 Sep 2026 07:00:00 -0400

The Company's Board of Directors believes that the market price of the Common Shares may not fully reflect the underlying value of the Company's business and future growth prospects. Consequently,

Form 6-K BIOHARVEST SCIENCES INC. For: Sep 15

Tue, 15 Sep 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260915/27065766.html

Form 6-K BIOHARVEST SCIENCES INC. For: Sep 15

Tue, 15 Sep 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260915/27065766.html

Form 6-K BIOHARVEST SCIENCES INC. For: Sep 15

Tue, 15 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260915/27065740.html

Form 6-K BIOHARVEST SCIENCES INC. For: Sep 15

Tue, 15 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260915/27065740.html

BioHarvest launches chewable version of its VINIA supplement

Tue, 15 Sep 2026 07:03:24 -0400

BioHarvest Sciences Inc. (NASDAQ: BHST) announced the launch of single-dose VINIA Daily Chews, a chewable format of its red-grape cell composition supplement, according to a company press release.

Each individually packaged Daily Chew delivers 400 mg of VINIA and 6 mg of piceid resveratrol, matching the dosage of the company's existing capsule format. The product is now available for purchase on the company's consumer website.

VINIA is described as a natural, non-GMO powder derived through the company's Botanical Synthesis platform, which produces plant-based compositions without growing the underlying plant. The chewable format is intended to reach consumers who prefer alternatives to traditional

BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product

Tue, 15 Sep 2026 07:00:00 -0400

Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the commercial versatility of Botanical Synthesis

Format expansion shows how BioHarvest can help CDMO partners move from plant-cell compositions to differentiated consumer products

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 15, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers and its own portfolio, today announced the launch of single-dose VINIA® Daily Chews. The new delivery format is designed to expand the addressable market for VINIA and to further demonstrate BioHarvest's progress toward leadership

BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product

Tue, 15 Sep 2026 07:00:00 -0400

Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the commercial versatility of Botanical Synthesis

Format expansion shows how BioHarvest can help CDMO partners move from plant-cell compositions to differentiated consumer products

Form 6-K BIOHARVEST SCIENCES INC. For: Sep 14

Mon, 14 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260914/27059210.html

Form 6-K BIOHARVEST SCIENCES INC. For: Sep 14

Mon, 14 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260914/27059210.html

BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Mon, 14 Sep 2026 07:00:00 -0400

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026, in New York City, NY. In addition to presenting, Dr. Rakib will also participate in one-on-one investor meetings throughout the conference.

CEO Zaki Rakib commented "We have recently announced several major advancements in our CDMO research and development programs, which includes securing

BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Mon, 14 Sep 2026 07:00:00 -0400

CEO Zaki Rakib commented "We have recently announced several major advancements in our CDMO research and development programs, which includes securing

BioHarvest Sciences seeks dual listing on Tel Aviv Stock Exchange

Thu, 03 Sep 2026 07:06:31 -0400

BioHarvest Sciences Inc. (NASDAQ: BHST) has filed to list its shares on the Tel Aviv Stock Exchange (TASE), the company announced, with trading expected to begin on September 8, 2026.

The company, currently listed on the Nasdaq Capital Market and the Frankfurt Stock Exchange (FSE: 8MV0), filed registration documents requesting that all outstanding and potential future shares be registered for dual listing on the TASE. The shares are expected to trade under the symbol BHST.

According to the registration filing, BioHarvest has requested to register 22,667,842 outstanding common shares, up to 4,516,021 common shares available for future issuance under its Equity Incentive

BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Thu, 03 Sep 2026 07:00:00 -0400

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026.

Dr Zaki Rakib, CEO of BioHarvest Sciences, commented, "BioHarvest is entering an exciting new phase of growth, built on the strength of our Botanical Synthesis platform and

BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Thu, 03 Sep 2026 07:00:00 -0400

Dr Zaki Rakib, CEO of BioHarvest Sciences, commented, "BioHarvest is entering an exciting new phase of growth, built on the strength of our Botanical Synthesis platform and